Teofilina

Theophylline

1. Identity: Chemical Names, Natural Sources, and Common Forms

1.1 Chemical and Botanical Identity

Theophylline, also known as 1,3-dimethylxanthine, is a drug that inhibits phosphodiesterase and blocks adenosine receptors. It is a methylxanthine compound characterized by two methyl groups attached to a xanthine molecule, structurally related to caffeine and theobromine, which are naturally occurring compounds found in certain foods and beverages. The chemical structure of theophylline is characterized by a xanthine nucleus with methyl groups at positions 1 and 3. The molecular formula of theophylline is C₇H₈N₄O₂, and its molecular weight is 180.17 g/mol.

The xanthine alkaloids — caffeine, theobromine, and theophylline — are closely related compounds found in a variety of plants indigenous to several continents. They are not true alkaloids, as they are only weakly basic, and possess some acidic properties. The name theophylline ("divine leaf") refers to the leaves of the tea plant, which contain a small amount of theophylline.

1.2 Natural Sources

Theophylline, 1,3-dimethylxanthine, is present in small quantities in tea leaves. It can occur in various natural sources like tea, cocoa, and coffee, or be synthesized by pyrimidine and imidazole rings. Theophylline is naturally found in cocoa beans. Amounts as high as 3.7 mg/g have been reported in Criollo cocoa beans. Trace amounts of theophylline are also found in brewed tea, although brewed tea provides only about 1 mg/L, which is significantly less than a therapeutic dose. Trace amounts of theophylline are also found in guarana (Paullinia cupana) and in kola nuts.

Theophylline occurs in black tea (Camellia sinensis) at very low levels; values cited in the literature vary greatly, but the most reliable range is 0.02–0.04% dry weight. Theophylline has been found in green coffee beans at approximately 5 mg/kg, and trace amounts were detected in cacao cotyledon. Theophylline was detected at 0.004% in dried mate. The total daily per-caput intake of theophylline in the USA was estimated to be 0.14 mg.

Caffeine and theobromine are the most abundant methylxanthines naturally occurring in a wide variety of foods and beverages, while theophylline is also present in some foods in minor amounts. Theobromine and theophylline are also derived from caffeine metabolism along with other secondary metabolites.

1.3 Common Preparations and Dosage Forms

Theophylline can be used as an oral agent (rapid or slow-release tablets, solution, syrup, or capsule) or in a more soluble form such as aminophylline (an ethylenediamine salt of theophylline) that can be dosed orally or intravenously. Aminophylline is a 2:1 complex of theophylline and ethylenediamine. Theophylline is structurally classified as a methylxanthine. Aminophylline (dihydrate) is approximately 79% of anhydrous theophylline by weight.

The extended-release tablets are absorbed slowly over 12 to 24 hours and provide a steady plasma concentration. Commercially, theophylline is produced in pharmaceutical manufacture by chemical synthesis rather than extraction from plant sources. The World Health Organization (WHO) includes theophylline on its List of Essential Medicines, recognizing its importance in basic healthcare systems.

2. Historical and Traditional Use

2.1 Discovery and Early Scientific History

Theophylline was first extracted from tea leaves and chemically identified around 1888 by the German biologist Albrecht Kossel. Seven years later, a chemical synthesis starting with 1,3-dimethyluric acid was described by Emil Fischer and Lorenz Ach. The Traube purine synthesis, an alternative method to synthesize theophylline, was introduced in 1900 by another German scientist, Wilhelm Traube.

It was extracted and synthesized in 1895 and initially used as a diuretic. Theophylline was extracted from tea leaves in 1888, its formula identified in 1895, and its bronchodilator action in animals established early in the 20th century. Although its potential value as a bronchodilator for asthma was noted in 1921, it was not immediately adopted for mainstream respiratory therapy. Since the 1950s, theophylline has been used as a drug for asthma treatment.

2.2 Traditional Medicinal Uses

The traditional use of theophylline as a pure compound is inseparable from the history of tea consumption, since brewed tea was the original source and vehicle. Theophylline has been used in traditional medicine for centuries to treat various respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). It was also used as a diuretic and a cardiac stimulant.

As an alkaloidal drug used in medicine, early applications included its use as an antiasthmatic, coronary vasodilator, and diuretic. Administered orally or rectally in the treatment of asthma, it facilitates breathing by relaxing the bronchioles in the lungs. It was administered by injection for the treatment of congestive heart failure to stimulate the heart and increase the total output of blood.

Theophylline, belonging to methylxanthines, has been a conventional oral bronchodilator for more than 100 years in COPD treatment. It was originally used as a bronchodilator, but the relatively high doses required are associated with frequent side effects, so its use declined as inhaled β₂-agonists became more widely used.

3. Key Constituents and Mechanisms of Action

3.1 Chemical Identity as the Active Compound

Unlike complex botanical extracts with multiple active constituents, theophylline is itself the singular active compound of interest — a pure methylxanthine molecule. Theophylline, a drug used for several decades, has several different actions at a cellular level, including inhibition of phosphodiesterase isoenzymes, antagonism of adenosine, enhancement of catecholamine secretion, and modulation of calcium fluxes.

3.2 Phosphodiesterase Inhibition

Similarly to other methylxanthines, theophylline has a dual mechanism of action: it is a non-selective competitive phosphodiesterase inhibitor, and also a non-selective competitive adenosine receptor antagonist.

PDE3 and PDE4 are two isoenzymes of the PDE family which are particularly important targets of theophylline action. PDE3 is present in smooth muscle cells and its inhibition results in smooth muscle relaxation in the airways, thus representing one of the pharmacological routes to bronchodilation. PDE4, on the other hand, is represented mostly in the cells of the immune system. Therefore, its inhibition suppresses inflammation as one of the main pathophysiological mechanisms involved in the development and worsening of bronchial asthma and COPD.

Studies in animals suggest that bronchodilation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV), while non-bronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Therapeutic levels of theophylline inhibited the phosphodiesterase-catalysed hydrolysis of cAMP and cGMP, but the percentage inhibition was relatively small. The results, while supporting the assumed contribution of phosphodiesterase inhibition to the overall mechanism of theophylline action, suggest that other presently unknown factors must also be taken into consideration to fully explain the beneficial effects of theophylline.

3.3 Adenosine Receptor Antagonism

Theophylline acts as a competitive nonselective phosphodiesterase inhibitor (inhibiting type III and type IV phosphodiesterase), which increases the concentration of intracellular cAMP, activates protein kinase A, inhibits TNF-alpha and leukotriene synthesis, and also decreases inflammation and innate immunity. It is also a nonselective adenosine receptor antagonist. It acts on A1, A2, and A3 receptors with almost the same affinity, which possibly explains theophylline's cardiac effects.

Theophylline blocks adenosine receptors, which has both therapeutic and toxic effects such as bronchodilation, tachycardia, cardiac arrhythmias, seizures, and cerebral vasoconstriction.

3.4 Histone Deacetylase Activation: The Anti-Inflammatory Mechanism

A distinct and more recently characterized mechanism of theophylline is its ability to activate histone deacetylases (HDACs) at low doses. More recently it has been shown to have anti-inflammatory effects in asthma and COPD at lower concentrations. The molecular mechanism of bronchodilatation is inhibition of PDE3 and PDE4, but the anti-inflammatory effect may be due to histone deacetylase (HDAC) activation, resulting in switching off of activated inflammatory genes. Through this mechanism theophylline also reverses corticosteroid resistance, and this may be of particular value in severe asthma and COPD where HDAC2 activity is markedly reduced.

Corticosteroids act, at least in part, by recruitment of histone deacetylases (HDACs) to the site of active inflammatory gene transcription. They thereby inhibit the acetylation of core histones that is necessary for inflammatory gene transcription. Both in vitro and in vivo, low-dose theophylline enhances HDAC activity in epithelial cells and macrophages. This increased HDAC activity is then available for corticosteroid recruitment and predicts a cooperative interaction between corticosteroids and theophylline.

This mechanism occurs at therapeutic concentrations of theophylline and is dissociated from phosphodiesterase inhibition (the mechanism of bronchodilation) or the blockade of adenosine receptors, which are partially responsible for its side effects. Synergism between theophylline and corticosteroids has been reported, wherein theophylline increases and restores the anti-inflammatory effects of inhaled corticosteroids (ICS) by enhancing HDAC activity. This effect is achieved at a low plasma concentration of theophylline (1–5 mg/L).

3.5 Additional Mechanisms

Theophylline causes the endogenous release of catecholamines through indirect stimulation of beta-1 and beta-2 receptors, which at therapeutic levels cause desired bronchodilation. Theophylline relaxes the smooth muscles located in the bronchial airways and pulmonary blood vessels. It also reduces the airway responsiveness to histamine, adenosine, methacholine, and allergens. Theophylline has been demonstrated to increase diaphragmatic muscle strength in healthy volunteers.

4. Scientific Evidence by Area of Use

4.1 Asthma — Chronic Maintenance

Recently, theophylline was found to have several immunomodulatory and anti-inflammatory properties, and thus interest in its use in patients with asthma has been renewed. The use of theophylline in the treatment of asthma and chronic obstructive pulmonary disease has diminished with the advent of new medications, but theophylline remains beneficial, especially in the patient with difficult refractory symptoms.

A considerable body of evidence has accumulated to show that theophylline has a wide range of pharmacological actions, in addition to the well-recognized action on airway smooth muscle function. Current evidence suggests that part of the therapeutic value of theophylline in the treatment of asthma is by virtue of an anti-inflammatory or immunomodulatory effect, although the actual mechanism of action remains unclear.

It has been proposed that the observed anti-inflammatory effects of theophylline could be attributed to phosphodiesterase (PDE) inhibition, and recently the type III and IV isoenzymes have been characterized in a number of inflammatory cells. Evidence shows that theophylline and the newer more selective type IV PDE isoenzyme inhibitors can inhibit the activation of inflammatory cell types, such as T-lymphocytes, eosinophils, mast cells and macrophages, in vitro. This body of in vitro evidence is considered preliminary as a basis for clinical application.

Bronchodilation occurs over the serum theophylline concentration range of 5 to 20 mcg/mL. Clinically important improvement in symptom control has been found in most studies to require peak serum theophylline concentrations >10 mcg/mL, but patients with mild disease may benefit from lower concentrations.

4.2 Asthma — Acute Exacerbations

A systematic review did not reveal any benefit of combined treatment of inhaled beta-mimetics with theophylline in the treatment of acute exacerbations of asthma compared to inhaled beta-mimetics alone in adults or children. IV aminophylline was previously a frequent therapy used to manage acute exacerbations of COPD and asthma but now sees much less frequent use, as it is far less effective than nebulized beta₂-agonists.

A 2016 systematic review examined the evidence for intravenous theophylline in children with acute asthma exacerbations. Ten RCTs and 2 observational studies were included. Children with serum levels between 10–20 mg/L did not have a reduction in duration of symptoms, length of hospital stay, or need for mechanical ventilation or better spirometric results compared with levels below 10 mg/L. These findings call into question the rationale for targeting higher serum concentrations in pediatric acute asthma.

4.3 Chronic Obstructive Pulmonary Disease (COPD)

Previous clinical studies indicated that theophylline could improve respiratory function and alleviate respiratory symptoms by strengthening of respiratory muscles, enhancing response to hypoxic ventilation, and thus increasing tidal volume. Guidelines suggest that theophylline has limitations in terms of its less efficacy in comparison with novel inhaled bronchodilators, narrow therapeutic window and adverse reactions. Current evidence regards theophylline as a third-line treatment of COPD and may be useful if other choices are unavailable or unaffordable.

A 2021 systematic review and meta-analysis (PLOS ONE, PROSPERO-registered) examining low-dose theophylline added to inhaled corticosteroids in COPD patients included 47,556 participants from 7 studies. The sample size of each study varied from 24 to 10,816. Theophylline as an add-on therapy to ICS was not associated with the reduction of COPD exacerbations (HR: 1.08, 95% CI: 0.97 to 1.19, I² = 95.2%). Instead, the theophylline group demonstrated a higher hospitalization rate (HR: 1.12, 95% CI: 1.10 to 1.15). Based on current evidence, low-dose theophylline as add-on therapy to ICS did not reduce the exacerbation rate. Instead, the hospitalization rate and mortality increased with theophylline. Thus, this analysis does not recommend adding low-dose theophylline to ICS therapy in COPD patients.

Despite this, a separate 2025 meta-analysis of theophylline added to inhaled therapy for stable COPD found: the absolute values of FEV₁ and FVC were enhanced with additional theophylline therapy, which might be explained in terms of relaxation of smooth muscle and anti-inflammatory effect of theophylline. However, there was no significant change in FEV₁% predicted and FEV₁/FVC%, which are more critical in reflecting small airway function and are likely to be considered important in clinical practice. Overall, the clinical evidence for theophylline in COPD is mixed and the current consensus positions it as a third-line or add-on agent.

4.4 Low-Dose Theophylline and Corticosteroid Synergy

Current research interests are drawn to low-dose theophylline due to its immunomodulatory and anti-inflammatory effect, synergistic with inhaled corticosteroids (ICS) by increasing HDAC2 activity. This molecular mechanism is defective in COPD patients as HDAC2 activity and expression is markedly reduced, thus accounting for the steroid resistance of COPD. There is also a defect in HDAC2 function in patients with severe asthma and in asthmatic patients who smoke. Theophylline is an activator of HDACs and enhances the anti-inflammatory effect of corticosteroids, as well as reversing steroid resistance in cells from COPD patients.

An animal study (2012, PubMed) in rats exposed to cigarette smoke demonstrated that the lung destruction index was restored to control levels with inhaled corticosteroid treatment in combination with a low, not a high, dose of theophylline. These results indicate that low-dose theophylline might provide protection from smoke damage and improve the anti-inflammatory effects of steroids by increasing HDAC-2 activity. This is animal evidence, and translation to human clinical outcomes remains under investigation.

4.5 Neonatal Apnea of Prematurity

Theophylline has been used to treat apnea in premature newborns. It helps stimulate the respiratory center in the brain, reducing the likelihood of apnea episodes in premature infants. In the United States, theophylline is largely used to treat bradycardia and apnea in premature newborns.

Theophylline is a safe, effective drug for the treatment of apnea of prematurity. The pharmacokinetics of theophylline have been studied extensively in preterm neonates. Compared to children and adults, prolonged half-life values and low clearance rates have been found: the apparent volume of distribution is larger and protein binding of the drug is decreased. A unique pattern of metabolism involving methylation to caffeine has been identified. Theophylline maintenance dose requirements are much lower in neonates than in children.

In neonatal dosing studies, a useful guide has been to give a loading dose of 5 mg/kg anhydrous theophylline followed by maintenance doses of 2 mg/kg every 12 hours. In many infants, this will suffice to prevent apnea without producing signs of toxicity. After commencement of therapy, doses must be individualized for each infant on the basis of serum theophylline concentration monitoring and monitoring for apnea. Note: caffeine has substantially replaced theophylline for neonatal apnea in high-resource clinical settings.

4.6 Cardiac and Diuretic Uses

Theophylline serves multiple therapeutic uses, among which bronchodilator effect, inhibition of phosphodiesterase enzyme, and dose-dependent effect on the CNS are a few well-mentioned activities. Some other therapeutic roles include stimulating gastric secretion, showing positive chronotropic and inotropic effects on the heart, and reducing contractility of smooth muscles.

In the future, theophylline may be used as treatment for bradyarrhythmias after cardiac transplantation, prophylactic medication to reduce the severity of nephropathy associated with intravenous administration of contrast material, therapy for breathing problems during sleep, and treatment for leukemias. These potential uses are exploratory and are based on emerging rather than established clinical evidence.

4.7 Sports Performance Enhancement

Theophylline and other methylxanthines are often used for their performance-enhancing effects in sports, as these drugs increase alertness, bronchodilation, and increase the rate and force of heart contraction. There is conflicting information about the value of theophylline and other methylxanthines as prophylaxis against exercise-induced asthma. This use lacks strong, dedicated clinical trial evidence.

5. Body Systems and Health Areas

• Respiratory system: Primary area of established use. Theophylline relaxes bronchial smooth muscle, reduces airway hyperresponsiveness, and has anti-inflammatory actions that are relevant to asthma and COPD. It relaxes the smooth muscles located in the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, adenosine, methacholine, and allergens.
• Cardiovascular system: Theophylline shows positive chronotropic and inotropic effects on the heart. Adenosine receptor antagonism can cause tachycardia and, at toxic levels, arrhythmias.
• Central nervous system: Methylxanthines cause central nervous system stimulation. At therapeutic doses, CNS effects include increased alertness and, potentially, irritability or insomnia.
• Renal system: Early historical use was as a diuretic. It was also used as a diuretic and a cardiac stimulant.
• Immune and inflammatory system: Theophylline inhibits TNF-alpha and leukotriene synthesis, and decreases inflammation and innate immunity.
• Skeletal/respiratory muscles: Theophylline has been demonstrated to increase diaphragmatic muscle strength in healthy volunteers. Increased respiratory muscle strength may benefit some patients on the verge of needing mechanical ventilation, or it may help wean patients from mechanical ventilation, though this effect has not been evaluated in a prospective randomized clinical trial.
• Neonatal respiratory system: Used to stimulate respiratory drive in apnea of prematurity, as noted above.

6. Dosage Forms and Reported Dosages

Bronchodilation occurs over the serum theophylline concentration range of 5 to 20 mcg/mL. At serum theophylline concentrations >20 mcg/mL, both the frequency and severity of adverse reactions increase. In general, maintaining peak serum theophylline concentrations between 10 and 15 mcg/mL will achieve most of the drug's potential therapeutic benefit while minimizing the risk of serious adverse events.

The recommended oral dose range for extended-release tablets is 400 to 600 mg/day. Those not currently taking theophylline should be given a loading dose of 5 to 7 mg/kg intravenously, followed by a maintenance dose of 0.4 to 0.6 mg/kg per hour intravenously to maintain serum concentrations at 10 to 15 mg/L.

Reported doses from published studies and prescribing sources:

• Acute bronchospasm (IV, adults without prior theophylline): Loading dose of 5–7 mg/kg intravenously or orally; not to exceed 25 mg/min intravenously. Aminophylline loading: 6–7 mg/kg intravenously over 20 minutes. Maintenance: 0.4–0.6 mg/kg/hour IV or 4.8–7.2 mg/kg orally (extended-release) every 12 hours to maintain levels 10–15 mg/L. For smokers: 0.79 mg/kg/hour IV for the next 12 hours after loading dose, then 0.63 mg/kg/hour.
• Low-dose HDAC-mediated anti-inflammatory effect: The synergistic anti-inflammatory effect with ICS via enhancement of HDAC activity is achieved at a low plasma concentration of theophylline (1–5 mg/L).
• Neonatal apnea of prematurity (published study dosing): A loading dose of 5 mg/kg anhydrous theophylline followed by maintenance doses of 2 mg/kg every 12 hours.
• Oral extended-release (chronic maintenance): Extended-release tablets are absorbed slowly over 12 to 24 hours and provide a steady plasma concentration. The recommended dose ranges from 400 to 600 mg/day.
• Dosing with CYP1A2-inhibiting drugs: When co-administered with drugs that decrease theophylline clearance (e.g., cimetidine, ciprofloxacin, and erythromycin and other macrolides): 0.2–0.3 mg/kg/hour IV or orally (extended-release) every 12–24 hours.

7. Pharmacokinetics

Theophylline is rapidly and completely absorbed after oral administration in solution or immediate-release solid oral dosage form. It does not undergo any appreciable pre-systemic elimination, distributes freely into fat-free tissues and is extensively metabolized.

The metabolism of theophylline in non-pregnant subjects is mainly by CYP1A2 (~88% of hepatic metabolism) and CYP2E1 (~12% of hepatic metabolism) with minor contributions from CYP2D6 and CYP3A4. Elimination of theophylline from the body occurs mainly (approximately 90%) by biotransformation, followed by excretion of the metabolites. Consequently, drugs affecting microsomal enzyme systems in the liver may alter the elimination of theophylline.

In preterm neonates compared to children and adults, prolonged half-life values and low clearance rates have been found; the apparent volume of distribution is larger and protein binding of the drug is decreased. A unique pattern of metabolism involving methylation to caffeine has been identified. Other factors like certain illnesses, tobacco use, marijuana use, and co-administration of other drugs can significantly alter theophylline clearance.

8. Safety Considerations and Drug Interactions

8.1 Narrow Therapeutic Window

Theophylline has a very narrow therapeutic window, and its interaction with various other drugs has led to the limitation of its use. The serum theophylline concentrations require monitoring directly to avoid toxicity, as the adverse effects of theophylline are related to its plasma concentration and have been observed when plasma concentrations exceed 20 mg/L. Some patients have also experienced adverse effects at low plasma concentrations.

Nausea, vomiting, and tachycardia are common signs of mild theophylline toxicity; seizures, ventricular arrhythmias, and hypotension are life-threatening manifestations of severe toxicity which may respond poorly to standard therapy. Although serum theophylline concentration correlates with toxicity in a general fashion, life-threatening adverse reactions are not readily predictable from the drug concentration alone.

The most common side effects are nausea and vomiting, headache, increased stomach acid secretion, and gastroesophageal reflux, which could be due to PDE inhibition.

8.2 Factors Altering Clearance

Theophylline clearance may decrease in patients with congestive heart failure, acute pulmonary edema, hepatic disease, cor pulmonale, acute hepatitis, hypothyroidism, cirrhosis, fever, or sepsis with multi-organ failure and shock. Theophylline clearance may be further reduced by concomitant diseases prevalent in the elderly, which further impair clearance of this drug and have the potential to increase serum levels and potential toxicity. These conditions include impaired renal function, chronic obstructive pulmonary disease, congestive heart failure, and hepatic disease.

Tobacco and marijuana smoking increase theophylline clearance by 50–100%, meaning smokers often need higher doses.

8.3 Drug–Drug Interactions

Theophylline interacts with a wide variety of drugs. The interaction may be pharmacodynamic — alterations in the therapeutic response to theophylline or another drug or occurrence of adverse effects without a change in serum theophylline concentration. More frequently, however, the interaction is pharmacokinetic — the rate of theophylline clearance is altered by another drug resulting in increased or decreased serum theophylline concentrations.

Key specific interactions verified in published sources include:

• Fluvoxamine (SSRI): Fluvoxamine is one of the most dangerous interactions — it can increase theophylline levels by up to 3 times, significantly raising the risk of seizures and cardiac arrhythmias. Theophylline should not be used in combination with the SSRI fluvoxamine.
• Ciprofloxacin: Concomitant use of theophylline and ciprofloxacin has decreased theophylline clearance and increased plasma levels and symptoms of toxicity. Serious and fatal reactions have included cardiac arrest, seizure, and status epilepticus. Several reports suggest that the combination of theophylline and ciprofloxacin has an additive inhibitory effect on gamma-aminobutyric acid (GABA) sites. Inhibition of the binding of GABA to its receptor sites has been related to the convulsant effects of other drugs.
• Erythromycin and troleandomycin: Erythromycin and troleandomycin decrease theophylline clearance by 25% and 50%, respectively.
• Cimetidine: The antiulcerative agent (H₂ antagonist) cimetidine decreases theophylline clearance by 30%.
• Rifampin: Rifampin (antituberculotic agent) increases theophylline clearance by 30%.
• Dose-dumping with lipid-based formulations: Some lipid-based formulations of theophylline can result in toxic theophylline levels when taken with fatty meals, an effect called dose dumping, but this does not occur with most formulations of theophylline.
• Pregnancy: Theophylline is excreted into breast milk and may cause irritability or other signs of mild toxicity in nursing human infants.

8.4 Toxicity Profile

Theophylline has a narrow therapeutic window, and even levels slightly above this therapeutic window can have many adverse effects in the setting of acute and chronic toxicity. The excess circulating catecholamines cause serious clinical effects that are associated with theophylline toxicity. Depending on the dose and route of administration, theophylline can have a wide range of cardiovascular, neurologic, metabolic, musculoskeletal, and gastrointestinal manifestations.

Small increases in serum concentrations can result in toxicity, particularly in patients with a level of more than 20 mg/L. Patients may experience serious symptoms of toxicity, such as convulsions and arrhythmias, before symptoms like nausea and vomiting appear.

Theophylline's pharmacokinetics are highly variable among individuals, necessitating tailored dosing and vigilant monitoring. Toxicity can manifest with nonspecific symptoms and may mimic other critical conditions, such as septic shock, underscoring the importance of prompt serum level measurement in unstable or decompensating patients.

References

• Jilani TN, Preuss CV, Sharma S. Theophylline. StatPearls. NIH/NCBI Bookshelf. Updated May 2023.
• Journey JD, Bentley TP. Theophylline Toxicity. StatPearls. NIH/NCBI Bookshelf. Updated June 2023.
• Aminophylline. StatPearls. NIH/NCBI Bookshelf. Updated July 2023.
• Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188(8):901–6. PMC4033977.
• Scurek R et al. A narrative review of theophylline: is there still a place for an old friend? Journal of Thoracic Disease. 2024.
• Hendeles L, Weinberger M. Theophylline: Recent Advances in the Understanding of Its Mode of Action and Uses in Clinical Practice. Mayo Clinic Proceedings. 1998.
• Cosio BG et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. PNAS. 2002;99(13):8921–6. PMC124399.
• Ito K, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. PNAS. 2002.
• Yang Y et al. Low-dose theophylline in addition to ICS therapy in COPD patients: A systematic review and meta-analysis. PLOS ONE. 2021. PMC8143407.
• Fang J et al. Effects of additional oral theophylline with inhaled therapy in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. PLOS ONE. 2025.
• Cooney L, Hawcutt D, Sinha I. The Evidence for Intravenous Theophylline Levels between 10–20 mg/L in Children Suffering an Acute Exacerbation of Asthma: A Systematic Review. PLOS ONE. 2016. PMC4838302.
• Torphy TJ. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J. 1995.
• Bergstrand H. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol. 1980. PubMed 215363.
• Pfeifer HJ, Greenblatt DJ, Friedman P. Therapeutic consequences of drug interactions with theophylline pharmacokinetics. J Clin Pharmacol. 1987. PubMed 2877015.
• Aranda JV et al. Pharmacokinetics of theophylline in neonates. J Pediatr. 1981. PubMed 7302609.
• Cosio BG et al. Low-dose theophylline restores corticosteroid responsiveness in rats with smoke-induced airway inflammation. PubMed. 2012. PubMed 22708526.
• IARC. Theophylline. In: Coffee, Tea, Mate, Methylxanthines and Methylglyoxal. IARC Monographs Vol. 51. NCBI Bookshelf.
• ScienceDirect Topics: Theophylline Derivative — an overview.
• Theophylline: Package Insert / Prescribing Information. Drugs.com.
• Sessler CN. Adverse Reactions and Interactions with Theophylline. Drug Safety. 1990. Springer.
• Theophylline. Encyclopædia Britannica.
• Theophylline. Wikipedia (citing primary pharmacological and clinical literature).
• Barnes PJ. Theophylline. Pharmaceuticals. 2010;3(3):725–747. MDPI.
• Lee J et al. Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants. Br J Clin Pharmacol. 2017. PMC5427230.
• Ghiculescu RA et al. Application of a Physiologically Based Pharmacokinetic Approach to Predict Theophylline Pharmacokinetics. Front Pharmacol. 2022. PMC9150776.
• Karki SD, Bentley DW, Raghavan M. Seizure with Ciprofloxacin and Theophylline Combined Therapy. Ann Pharmacother. 1990.
• Theophylline Interactions. The Pharmaceutical Journal (Royal College of Pharmacy).